官方服务：
资源简介：
Co-treatment of Har/se against cardiac hypertrophy
应用场景：
创建时间：
2023-07-18
相关数据集
Inhibition of Jumonji demethylases transcriptionally reprograms severe cardiac hypertrophy and prolongs survival: part 2.
Cardiac hypertrophy is a potentially fatal disease characterized by increased cardiomyocyte size, and maladaptive transcriptional remodeling that leads to arrythmias and contractile failure. Transgeni
NIAID Data Ecosystem30
Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways
Aliskiren (ALS) is well known for its antihypertensive properties. However, the potential underlying the molecular mechanism and the anti-hypertrophic effect of ALS have not yet been fully elucidated.
NIAID Data Ecosystem30
DataSheet1_Bawei Chenxiang Wan Ameliorates Cardiac Hypertrophy by Activating AMPK/PPAR-α Signaling Pathway Improving Energy Metabolism.ZIP
Bawei Chenxiang Wan (BCW), a well-known traditional Chinese Tibetan medicine formula, is effective for the treatment of acute and chronic cardiovascular diseases. In the present study, we investigated
NIAID Data Ecosystem20
Inhibition of Jumonji demethylases transcriptionally reprograms severe cardiac hypertrophy and prolongs survival.. Inhibition of Jumonji demethylases transcriptionally reprograms severe cardiac hypertrophy and prolongs survival.
Cardiac hypertrophy is a potentially fatal disease characterized by increased cardiomyocyte size, and maladaptive transcriptional remodeling that leads to arrythmias and contractile failure. Transgeni
NIAID Data Ecosystem30
DataSheet1_Oxytocin Protects Against Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting PI3K/AKT Pathway via a lncRNA GAS5/miR-375-3p/KLF4-Dependent Mechanism.PDF
Cardiac hypertrophy is caused by cardiac volume or pressure overload conditions and ultimately leads to contractile dysfunction and heart failure. Oxytocin (OT), an endocrine nonapeptide, has been ide
NIAID Data Ecosystem20
